Dongfang Liu - 17 Nov 2025 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Stephen Dang, Attorney-in-Fact
Issuer symbol
NUVB
Transactions as of
17 Nov 2025
Transactions value $
-$91,928
Form type
4
Filing time
19 Nov 2025, 16:47:31 UTC
Previous filing
06 May 2025
Next filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Liu Dongfang CHIEF MEDICAL OFFICER C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK /s/ Stephen Dang, Attorney-in-Fact 19 Nov 2025 0001937915

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVB Class A Common Stock Options Exercise $28.1K +15K +100% $1.87 30K 17 Nov 2025 Direct F1
transaction NUVB Class A Common Stock Sale -$71.5K -15K -50% $4.77 15K 17 Nov 2025 Direct
transaction NUVB Class A Common Stock Options Exercise $28.1K +15K +100% $1.87 30K 19 Nov 2025 Direct
transaction NUVB Class A Common Stock Sale -$76.6K -15K -45.45% $5.10 18K 19 Nov 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVB Stock Option (Right to Buy) Options Exercise $0 -15K -3% $0.00 485K 17 Nov 2025 Class A Common Stock 15K $1.87 Direct F4
transaction NUVB Stock Option (Right to Buy) Options Exercise $0 -15K -3.09% $0.00 470K 19 Nov 2025 Class A Common Stock 15K $1.87 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,000 shares acquired on May 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
F2 Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.21. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 Includes 3,000 shares acquired on November 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
F4 Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.